I did receive my 1099 concerning IOFIX; my shares are held with the transfer agent; not a brokerage.
We receive a Form 2439 (Notice to Shareholder of Undistributed Long-Term Capital Gains) for the same company; one is from the transfer agent and the other one is from the brokerage. Form 2439 from the transfer agent is generally received weeks ahead of the one from the brokerage.

I wonder whether IOFIX informs brokerages like Fidelity or TD that in 2020 about half of its distributions were not dividends but return of capital (ROC)? When I talked to IOFIX and Fidelity, they said that I should not worry and everything will be properly mentioned in 1099, but I have heard from a friend with an account at TD that this may not be the case.
So I wonder whether anybody received 1099 correctly describing dividends and ROC in the distributions of IOFIX? Any other related experience/comments?

I "love" Grantham/GMO predictions
12/31/2020 (link) 7 year prediction were: US LC will make 0.4% + 2.5% = 2.9% annually. EM will make 4.1%+2.5% inflation=6.6%. The real results(link) show SPY=13.65 annually EEM=1.9% annually
2012(link): "Jeremy Grantham Warns 2013 Will Be A Dangerous Year For Stocks". 2013 results: VFIAX 32.3%.
2015(link>): "GMO founder Grantham says markets ‘ripe for major decline’ in 2016". The results: +11.9%
Why do they keep listening to him? Panic and bad news sell....wait, I know, one day the market will crash, what a story.

follow-up:
https://www.sec.gov/Archives/edgar/data/1545440/000139834421003462/fp0062438_497.htm
497 1 fp0062438_497.htm
February 16, 2021
KARNER BLUE BIODIVERSITY IMPACT FUND
Investor Class (KAIAX)
Institutional Class (KAIIX)
ButterflyTM Class (KAIBX)
Each A Series of Ultimus Managers Trust
Supplement to Summary Prospectus, Prospectus, and Statement of Additional Information dated September 28, 2020
This supplement updates certain information in the Summary Prospectus (“Summary Prospectus”), the Prospectus (“Prospectus”) and the Statement of Additional Information (“SAI”) of the Karner Blue Biodiversity Impact Fund (the “Fund”), a series of the Ultimus Managers Trust. For more information or to obtain a copy of the Fund’s Summary Prospectus, Prospectus or SAI, free of charge, please visit the Fund’s website at www.biodiversityimpactfund.com or call the Fund toll free at 1-855-KBANIML (855-522-6465).
Closure and Conversion of Shares
On March 18, 2021, all existing shares of the Investor Class and Institutional Class of the Fund will be converted into shares of the ButterflyTM Class of the Fund (the “Conversion”). There will be no fees charged in connection with the Conversion. After the Conversion, the Fund will offer only a single class of shares – the ButterflyTM Class.
There are no tax consequences anticipated with the Conversion, and no action is necessary on your part to effect the Conversion. Shareholders should consult with their own tax advisors to ensure proper treatment on their income tax returns.
Shareholders may continue to purchase and redeem Investor Class and Institutional Class shares of the Fund on each business day until the Conversion on March 18, 2021.
After the Conversion, all references to the Investor Class and Institutional Class of the Fund are hereby struck from the Fund’ Summary Prospectus, Prospectus, and SAI.
Changes to the ButterflyTM Class Shares
Effective on February March 18, 2021, the minimum initial investment amount for ButterflyTM Class shares of the Fund will be $2,000. References in the Fund’s Summary Prospectus and Prospectus to the ButterflyTM Class’ minimum investment amounts in the section titled “Purchase and Sale of Fund Shares” and in the section titled “How to Buy Shares” are hereby modified accordingly.
Also Effective on March 18, 2021, the ButterflyTM Class of the Fund will be subject to the Fund’s Administrative Service Plan, and may make service fee payments to financial intermediaries for certain administrative, recordkeeping, and other non-distribution related services at an annual rate of up to 0.10% of the Fund’s average daily net assets. The Administrative Service Plan and the accompanying fee, is identical to that which applied to the Institutional Class shares of the Fund, and the section in the Fund’s Prospectus and SAI titled “Administrative Services Plan” should now be read to apply to the ButterflyTM Class of the Fund, rather than to the Institutional Class.
Change to the Investment Adviser’s Address
Effective immediately, the address of the Fund’s investment adviser, Karner Blue Capital, LLC, is as follows:
Karner Blue Capital, LLC
7315 Wisconsin Avenue #650W
Bethesda, MD 20814
All references to the address of the Fund’s investment adviser in the Prospectus and SAI are hereby modified accordingly.
If you have any questions regarding the Fund, please call 1-855-KBANIML (855-522-6465).

Taking reports of side effects now the vaccines have been given to over 40 million people is fraught with difficulty, as there is no longer a placebo group to compare to. Anyone who has a serious medical problem after the vaccine will likely be reported to the FDA but that does not mean that the vaccine caused the stoke or heart attacks or whatever. The frequency of adverse reaction the FDA reports in post marketing studies are reflective of whatever reports they receive.
30,000 people were in both of the Pfizer and Moderna studies which is a huge number. It is large enough to give us confidence that the most serious side effects would show up, and could be compared to their frequency in the placebo group.
I would suggest people who are interested read the original FDA data both Moderna and Pfizer submitted. You can quickly go to the section on side effects and see the actual data that compares the vaccine recipients to their placebo counterparts. The tables are clear and easy to follow.
Here is Moderna
https://www.fda.gov/media/144434/download
The text for "deaths" follows.
"Serious Adverse Events Deaths As of December 3, 2020, 13 deaths were reported (6 vaccine, 7 placebo). Two deaths in the vaccine group were in participants >75 years of age with pre-existing cardiac disease; one participant died of cardiopulmonary arrest 21 days after dose 1, and one participant died of myocardial infarction 45 days after dose 2. Another two vaccine recipients were found deceased at home, and the cause of these deaths is uncertain: a 70-year-old participant with cardiac disease was found deceased 57 days after dose 2, and a 56-year-old participant with hypertension, chronic back pain being treated with opioid medication died 37 days after dose 1 (The official cause of death was listed as head trauma). One case was a 72-year-old vaccine recipient with Crohn’s disease and short bowel syndrome who was hospitalized for thrombocytopenia and acute kidney failure due to obstructive nephrolithiasis 40 days after dose 2 and developed complications resulting in multiorgan failure and death. One vaccine recipient died of suicide 21 days after dose 1. The placebo recipients died from myocardial infarction (n=3), intra-abdominal perforation (n=1), systemic inflammatory response syndrome in the setting of known malignancy (n=1), COVID-19 (n=1), and unknown cause (n=1). These deaths represent events and rates that occur in the general population of individuals in these age groups.
Non-fatal Serious Adverse Events Among participants who received at least one dose of vaccine or placebo (N=30,351), the proportion of participants who reported at least one SAE from dose 1 to the primary analysis cutoff date (November 25, 2020) was 1% in the mRNA-1273 group and 1% in the placebo group. The most common SAEs occurring at higher rates in the vaccine group than the placebo group were myocardial infarction (0.03% in vaccine group, 5 cases vs. 3 cases in placebo group), cholecystitis (0.02% in vaccine group, 3 cases vs. 0 cases in placebo group), and nephrolithiasis (0.02% in vaccine group, 3 cases vs. 0 cases in placebo group). The small numbers of cases of these events do not suggest a causal relationship. The most common SAEs occurring at higher rates in the placebo arm than the vaccine arm, aside from COVID-19 (0.1% in placebo group), were pneumonia (0.05% in placebo group) and pulmonary embolism (0.03% in placebo group). Occurrence of other SAEs, including cardiovascular SAEs, were otherwise balanced between treatment groups. "
I think it is fair to say these vaccines are very safe, and at least so far, very very effective

I listened to that Grantham interview on Bloomberg 2-3 times one day recently. He lays out a convincing case. But there are equally good arguments on both sides.
As far as Grantham’s argument goes he’s focused on three areas: (1) He thinks artificial risk asset impetus has been supplied from over a decade of easing by the Fed and other central banks. Since he doesn’t think this can continue much longer (deficits / unrealistically low rates) he sees an eventual popping of the “bubble”. (2) He sees a near hysterical chasing of return today irregardless of risk - a euphoria he equates with the final stages of bull markets. (3) He takes issue with high valuations in some sectors - technology particularity.
It should be noted that Grantham is more sanguine re value stocks, thinking there are pockets of opportunity in that depressed sector. He sounds downright bullish on emerging markets - if one has a long enough time horizon.
Each investor needs to consider his own time frame, risk tolerance, overall financial situation before undertaking any changes. I’ve grown a bit more cautious over the past couple months. The last two years were good to most investors. So, irrespective of Grantham, I see no compelling reason for a retiree to be overly aggressive at this point. I’m sharing how my allocation has changed in recent months as I try to protect 50+ years of accumulated retirement savings. Your situation is doubtless different and so should be your approach.
* End of 2020: Alternatives 25%, Equity/Balanced Funds 25%, Diversified Bond 25%, Cash & cash alternatives 15%, Real Assets & Commodity 10%.
* Today: Alternatives 33%, Equity/Balanced 20%, Diversified Bond 20%, Cash & cash alternatives 15%, Real Assets & Commodity 7%, Benchmark Fund (PRSIX) 5%.
Explanatory Notes:
- TMSRX accounts for about 50% of the alternative portion. PRPFX comprises most of the rest.
- I’ve gone much shorter on the diversified bond holdings. DODLX is the riskiest one at 50%. The rest consists of short term bond funds like newly opened TSDLX.
- I’ve moved most of the cash into a medium duration TIPS index fund,
- I’ve switched from TRRIX to PRSIX as my benchmark and have added a small allocation to that fund. One difference between the two above funds ... PRSIX commits 0-10% to a Blackstone hedge fund. TRRIX does not.
- There remains a small spec position in a mining fund.

Thankyou all
You can also report severe side effects to your Healthcare agency and they may forward info to cdc
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html
Adverse Reactions
Up-to-date
https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-vaccines-to-prevent-sars-cov-2-infection
The following adverse reactions and incidences are derived from the FDA issued emergency use authorizations (EUAs) unless otherwise specified. Refer to EUAs for specific vaccines for information regarding reporting adverse reactions (FDA 2020; FDA 2021c).
>10%:
Gastrointestinal: Diarrhea (Pfizer: 8% to 11% [placebo: 6% to 12%]; higher in younger patients), nausea and vomiting (Moderna: 9% to 21% [placebo: 4% to 8%]; higher in younger patients and with second dose)
Local: Pain at injection site (66% to 90% [placebo: 8% to 19%]; higher in younger patients), swelling at injection site (4% to 13% [placebo: 0.2% to 1.2%])
Nervous system: Chills (Moderna: 5% to 49%; Pfizer: 6% to 35% [placebo: 3% to 6%]; higher in younger patients and with second dose), fatigue (33% to 68% [placebo: 17% to 33%]; higher in younger patients and with second dose), headache (Moderna: 25% to 63%; Pfizer: 25% to 52% [placebo: 18% to 34%]; higher in younger patients and with second dose)
Neuromuscular & skeletal: Arthralgia (Moderna: 16% to 46%; Pfizer: 9% to 22% [placebo: 4% to 12%]; higher in younger patients and with second dose), axillary swelling (Moderna: Including axillary tenderness; 6% to 16% [placebo: 3% to 5%]; higher in younger patients), myalgia (Moderna: 20% to 62%; Pfizer: 14% to 37% [placebo: 5% to 14%]; higher in younger patients and with second dose)
Miscellaneous: Fever (<1% to 16% [placebo: 0.1% to 0.9%]; higher in younger patients and with second dose)
1% to 10%:
Gastrointestinal: Nausea (Pfizer: 1%), vomiting (Pfizer: <1% to 2% [placebo: 0.3% to 1.2%]; higher in younger patients)
Hematologic & oncologic: Lymphadenopathy (≤1% [placebo: <0.1% to 0.6%]; unsolicited) (Polack 2020)
Hypersensitivity: Hypersensitivity reaction (Moderna: Including injection site rash and injection site urticaria; 2% [placebo: 1.1%])
Local: Erythema at injection site (2% to 9% [placebo: 0.4% to 1.1%])
<1%: Nervous system: Malaise (Pfizer)
Frequency not defined:
Dermatologic: Facial swelling (Moderna)
Gastrointestinal: Appendicitis (Pfizer; unsolicited; data insufficient to determine causal relationship)
Hypersensitivity: Anaphylaxis (CDC 2021; CDC/FDA 2021a; CDC/FDA 2021b)
Local: Local swelling (at or near the site of dermal fillers [eg, face or lips]) (CDC 2021)
Nervous system: Bell’s palsy (unsolicited; data insufficient to determine causal relationship)
Neuromuscular & skeletal: Joint injury (shoulder; unsolicited) (Polack 2020)

@Crash Two different Browns: Brown Capital Management vs. Brown Advisory.

Last Sunday, 7 February, all ratings were updated on our MFO Premium site, including MultiSearch, Great Owls, Fund Alarm (Three Alarm and Honor Roll), Averages, Dashboard of Profiled Funds, Portfolios, QuickSearch, and Fund Family Scorecard. The site now includes several analysis tools, including Correlation, Rolling Averages, Trend, Ferguson Metrics, Calendar Year and Period Performance.
Today, we launched a new tool for premium subscribers: "Dashboard of Launch Alerts."
The "Launches Dashboard" compiles and tracks funds first appearing in our "Launch Alert" feature of the monthly MFO commentary. It follows a format similar to the Profiles Dashboard, but lists funds by alert date, most recent on top to oldest on bottom, since MFO launched in May 2011.
Hundreds of new funds are launched annually (e.g., 590 in 2020), but most are not worth mentioning. David highlights just a dozen or so each year.
When a manager with a strong record leaves an established firm to start anew, David lets us know:

• Andrew Foster created Seafarer Capital Partners, LLC and launched Seafarer Overseas Growth and Income (SIGIX), as discussed in the February 2012
  commentary.
  


• Laura Geritz created Rondure Global Advisors, LLC and launched
  Rondure New World (RNWIX) in 2016.

As he does when an established firm of high stewardship launches a fund in a new market:

• Vanguard Emerging Markets Government Bond Index (VWOB) in the March 2013 commentary.


• T Rowe Price Total Return (PTTFX) in December 2016.

Usually, the Launch Alerts contain a paragraph or two describing why the fund may be worthy. Some are longer than others, a kind of mini-profile:

• Towpath Focus (TOWFX) launched by Mark Oelschlager and highlighted in September 2020 feature.
  

Since 2016, MFO breaks-out Launch Alerts in the new magazine format. Before that, they were included in the long-scroll format.
Many of the funds in Launch Alert have gone-on to do quite well, some spectacularly. While about 1-in-6, as of January 2021, end-up in the dust bin (not shown, e.g., Whitebox Funds).
As an adviser or individual investor, I would check this list often.
Premium subscribers can access the new tool here. QuickSearch, Great Owls, Three Alarm, and Profiles tools remain available to the public without subscription.
Enjoy!

Howdy @JonGaltIII
Since the 2010 census, about 10,000 baby boomers a day (retire, too) have crossed the age 65 threshold and by 2030, all boomers will be at least age 65. From 2019 data the boomers are about 72 million in population. Our house is boomers x 2. While there are now and will be failures of individual holdings within healthcare, I still fully consider this a growth area for equity. These folks will require more maintenance than the under 40 age group, yes? There will be the fails of hospitals, health insurance companies and the best laid plans for the next magic drug. There will likely also be continued mergers and acquisitions of big and small companies in many areas. This sector has had its recent funky periods (2015-2016), so it is not a slam dunk; but I still have faith in the broad sectors.
From the devils advocate perspective, One would have to perform an overview of personal holdings to discover how much exposure your holdings have to healthcare now and how much you desire. The 3 below breakdowns give a hint to health sectors from various funds.
Our own personal perspective is provide equity exposure that is meaningful to performance of the entire portfolio. We generally do not hold less than 10% of total portfolio in a given investment area. Performance may allow this number to become 25%; but this is an individuals judgement; based upon portfolio risk and faith in the sector.
Our healthcare holdings travel the road between United Healthcare and genomics and whatever else is in the mix. The healthcare holdings over the years has more than paid for our supplemental insurance plans via United Healthcare. Invest in what you (and many others) use.
Though FSMEX is currently open, the last hard close was a no-notify close at the end of a business; without a grace period.
Lastly, if one were to have a full tour of various medical areas in a large hospital; you'd be able to view a large number of products from companies where you hold investments.
My 2 cents worth.
Take care,
Catch
AS OF 12/31/2020
FSPHX Portfolio Weight
Biotechnology 24.27%
Health Care Equipment 20.25%
Managed Health Care 18.10%
Pharmaceuticals 18.03%
Health Care Services 8.04%
Life Sciences Tools & Services 6.93%
Health Care Technology 1.51%
Health Care Facilities 1.36%
Application Software 0.65%
Research & Consulting Services 0.29%
Other Diversified Financial Services 0.08%
Investment Banking & Brokerage 0.02%
FSMEX Portfolio Weight
Health Care Equipment 55.23%
Life Sciences Tools & Services 23.09%
Managed Health Care 5.75%
Health Care Supplies 3.90%
Health Care Technology 3.79%
Health Care Services 3.46%
Biotechnology 2.34%
Application Software 0.86%
Insurance Brokers 0.52%
Apparel, Accessories & Luxury Goods 0.38%
Research & Consulting Services 0.36%
Textiles 0.22%
Investment Banking & Brokerage 0.03%
FSPGX Portfolio Weight (likely a typical growth index weighting)
Information Technology 44.88%
Consumer Discretionary 16.67%
Health Care 13.49%
Communication Services 10.99%
Consumer Staples 4.53%
Industrials 4.51%
Financials 1.86%
Real Estate 1.61%
Materials 0.80%
Multi Sector 0.54%
Energy 0.08%
Utilities 0.02%

Interesting reading here. I owned FSELX for a while. I subscribed to the notion that AI will be growing and semiconductors is a prudent long term high growth play. It probably still is but the gyrations with NVidia and Intel - I couldn't take the volatility and sold it. It was probably a mistake. Long term... this is likely a good bet.
Another fund I had was @Puddnhead FSDAX . I bought it 5 years ago before the last administration took office. It was a pure guess that a focus on Defense and build up would be positive for this fund. I did sell it in late 1999 or early 2020 (I can't recall exactly when). Pudd - are you still in it?
I save a little space to speculate in sector funds or "trending" spaces. In 2021 - I'm in EM + Small Cap + Healthcare as my trending...

I'm wary about SPACs (aka "blank check" companies).
When created, they usually don't own any companies so performing proper due diligence is impossible.
Some companies that could not bear the scrutiny of the IPO process are going public via SPACs.
SPAC sponsors may put up relatively little of their own money but often receive a 20% stake after a merger is completed. Speculation is fueling the recent popularity of SPACs.
Sponsors may reap considerable profits, but I don't think this will end well for many retail investors.
Link1
Link2

@msf makes valid points regarding GP’s exposure to certain favorite stocks and the difference between BCISX and GP funds. BCSIX now holds $8B+ spread among 41 positions, holds no international stocks, and is a different animal from any GP fund. Probably due to its growth, BCSIX is no longer a SCG fund, but MCG. When I first bought it, this was not the case. I have never been able to figure out why the Brown Capital method does not work for their MCG fund, BCMSX, a true plodder. If BCSIX can’t stay above the thirtieth percentile in its category, it might be an indication that it’s no longer the winner it once was. I don’t want to sell BCSIX, but I’m adding any new dollars to Driehaus if I want true SCG coverage. I think BCSVX, which has $ I used to have in Grandeur Peak, continues to be a great foreign growth offering.

@bee, thank you for posting. This WealthTrack is particularly informative.
You asked a few questions.
1. Treasury. Low bond yields prevent treasuries to rally on the upside. He suggested holding some longer term treasury since they have lesser correlation to stocks comparing to other bond asset classes.
2. PRWCX is not a risk managed equity fund since all stock and bond positions are long. It is, however, a highly flexible asset allocation fund. Risk managed equity typically have several components within the portfolio to short the market as part of the downside protection. Some examples are listed in Calamos funds below.
https://calamos.com/blogs/investment-ideas/calamos-risk-managed-funds-show-resilience-in-march-madness/
Although Pimco bond funds are not considered hedge funds, they use swaps and other instruments routinely to reduce the drawdowns.
T. Rowe Price does have an alternative fund, Multi-strategy total return fund, TMSRX
quotes.morningstar.com/chart/fund/chart?t=tmsrx
@David Snowball also profiled this fund last year in great details.
https://mutualfundobserver.com/2020/07/t-rowe-price-multi-strategy-total-return-tmsrx/#more-14321
In addition, @Charles Bolin contributed a very nice article in MFO's commentary last year. Table 2 contains lots of alternative funds/ETFs to consider. Charles obtained these information from the MFO Premium Lipper's database.
https://mutualfundobserver.com/2020/09/alternative-and-global-funds-during-a-global-recession/#more-14509

LA Times: The FDA didn’t ‘approve’ Pfizer’s COVID-19 vaccine.
https://www.latimes.com/science/story/2020-12-12/why-fda-didnt-approve-pfizer-covid-19-vaccine-eua

In the case of a vaccine, authorization can be granted if “the known and potential benefits outweigh the known and potential risks,” the FDA says.

Some (most?) people equate that with "generally safe"; I read it as "safe enough".
In anticipation of "look at the evidence" response, here's more from the LA Times:

• It was 95% effective at preventing cases of COVID-19 in both Latinos and non-Latinos.
• It was 100% effective in Black people.
• It was 94% effective in people who were at least 56 years old. (The older you get, the greater the risk of a serious case of COVID-19.)
• It was 95% effective in those who had at least one medical condition that made them more likely to develop a serious case of COVID-19.
• It was 96% effective for people who were obese, another condition that makes people more vulnerable to COVID-19.
Yet none of this was enough for the vaccine to win official FDA approval.

One can certainly disagree with the FDA and assert that the vaccines are "generally safe", i.e. safe for general (not just emergency) use. Everyone is entitled to an opinion.

I have a small position in FSPHX and have had it for a while. I've been taking a closer look at FSMEX and I can't come up with a reason to keep FSPHX over FSMEX. Using premium... PRHSX and SHSAX along with a newcomer I've been watching ETIHX comes up. But it just seems FSMEX is far and away the consistent performer - looking at APR vs. Peer, Ulcer, Martin and DD. It has been outperforming my current FSPHX which had a tough 2020 in the vs. peer category. That said, it's beaten the S&P 500 consistently since it's inception. But so has FSMEX.
Just wondering if anyone has an opinion.

updated:
https://www.sec.gov/Archives/edgar/data/915802/000139834421003133/fp0062314_497.htm
497 1 fp0062314_497.htm
FINANCIAL INVESTORS TRUST
Emerald Small Cap Value Fund
(the “Fund”)
Supplement dated February 12, 2021
to the Fund’s Prospectus and Statement of Additional Information
dated August 31, 2020, as supplemented
As previously disclosed, on December 8, 2020, the Board of Trustees (the “Board”) of Financial Investors Trust (the “Trust”), based upon the recommendation of Emerald Mutual Fund Advisers Trust (the “Adviser”), the investment adviser to the Fund, a series of the Trust, determined to close and liquidate the Fund on or about January 11, 2021. The date for such liquidation is now expected to be on or about February 26, 2021 (the “Liquidation Date”).
If the Fund has not received your redemption request or other instruction prior to the close of business on the Liquidation Date, your shares will be redeemed, and you will receive proceeds representing your proportionate interest in the net assets of the Fund as of the Liquidation Date, subject to any required withholdings. As is the case with any redemption of fund shares, these liquidation proceeds will generally be subject to federal and, as applicable, state and local income taxes if the redeemed shares are held in a taxable account and the liquidation proceeds exceed your adjusted basis in the shares redeemed. If the redeemed shares are held in a qualified retirement account such as an IRA, the liquidation proceeds may not be subject to current income taxation under certain conditions. You should consult with your tax adviser for further information regarding the federal, state and/or local income tax consequences of this liquidation that are relevant to your specific situation.
PLEASE RETAIN THIS SUPPLEMENT FOR FUTURE REFERENCE

https://www.sec.gov/Archives/edgar/data/1545440/000139834421003163/fp0062350_497.htm
97 1 fp0062350_497.htm
February 12, 2021
KARNER BLUE BIODIVERSITY IMPACT FUND
Investor Class (KAIAX)
Institutional Class (KAIIX)
ButterflyTM Class (KAIBX)
Each A Series of Ultimus Managers Trust
Supplement to Summary Prospectus, Prospectus, and Statement of Additional Information
dated September 28, 2020
This supplement updates certain information in the Summary Prospectus (“Summary Prospectus”), the Prospectus (“Prospectus”) and the Statement of Additional Information (“SAI”) of the Karner Blue Biodiversity Impact Fund (the “Fund”), a series of the Ultimus Managers Trust. For more information or to obtain a copy of the Fund’s Summary Prospectus, Prospectus or SAI, free of charge, please visit the Fund’s website at www.biodiversityimpactfund.com or call the Fund toll free at 1-855-KBANIML (855-522-6465).
Closure and Conversion of Shares
Effective immediately, all sales and acceptance of purchase orders for shares of the Investor Class and Institutional Class of the Fund shall be discontinued.
On March 18, 2021, all existing shares of the Investor Class and Institutional Class of the Fund will be converted into shares of the ButterflyTM Class of the Fund (the “Conversion”). There will be no fees charged in connection with the Conversion. After the Conversion, the Fund will offer only a single class of shares – the ButterflyTM Class.
There are no tax consequences anticipated with the Conversion, and no action is necessary on your part to effect the Conversion. Shareholders should consult with their own tax advisors to ensure proper treatment on their income tax returns.
Shareholders may continue to redeem their Investor Class and Institutional Class shares of the Fund on each business day until the Conversion on March 18, 2021.
After the Conversion, all references to the Investor Class and Institutional Class of the Fund are hereby struck from the Fund’ Summary Prospectus, Prospectus, and SAI.
Changes to the ButterflyTM Class Shares
Effective on February March 18, 2021, the minimum initial investment amount for ButterflyTM Class shares of the Fund will be $2,000. References in the Fund’s Summary Prospectus and Prospectus to the ButterflyTM Class’ minimum investment amounts in the section titled “Purchase and Sale of Fund Shares” and in the section titled “How to Buy Shares” are hereby modified accordingly.
Also Effective on March 18, 2021, the ButterflyTM Class of the Fund will be subject to the Fund’s Administrative Service Plan, and may make service fee payments to financial intermediaries for certain administrative, recordkeeping, and other non-distribution related services at an annual rate of up to 0.10% of the Fund’s average daily net assets. The Administrative Service Plan and the accompanying fee, is identical to that which applied to the Institutional Class shares of the Fund, and the section in the Fund’s Prospectus and SAI titled “Administrative Services Plan” should now be read to apply to the ButterflyTM Class of the Fund, rather than to the Institutional Class.
Change to the Investment Adviser’s Address
Effective immediately, the address of the Fund’s investment adviser, Karner Blue Capital, LLC, is as follows:
Karner Blue Capital, LLC
7315 Wisconsin Avenue #650W
Bethesda, MD 20814
All references to the address of the Fund’s investment adviser in the Prospectus and SAI are hereby modified accordingly.
If you have any questions regarding the Fund, please call 1-855-KBANIML (855-522-6465).

https://www.sec.gov/Archives/edgar/data/915802/000139834421003172/fp0062329_497.htm
497 1 fp0062329_497.htm
FINANCIAL INVESTORS TRUST: GRANDEUR PEAK FUNDS
GRANDEUR PEAK EMERGING MARKETS OPPORTUNITIES FUND
GRANDEUR PEAK GLOBAL MICRO CAP FUND
GRANDEUR PEAK GLOBAL OPPORTUNITIES FUND
GRANDEUR PEAK INTERNATIONAL OPPORTUNITIES FUND
GRANDEUR PEAK INTERNATIONAL STALWARTS FUND
(Each, a “Fund,” and together, the “Funds”)
SUPPLEMENT DATED FEBRUARY 12, 2021 TO THE SUMMARY PROSPECTUS AND PROSPECTUS OF THE FUNDS DATED AUGUST 31, 2020, AS SUPPLEMENTED FROM TIME TO TIME
Effective as of the close of business on February 26, 2021, the Grandeur Peak Global Opportunities Fund, Grandeur Peak International Opportunities Fund, Grandeur Peak International Stalwarts Fund and Grandeur Peak Global Micro Cap will no longer accept purchases, from new or existing investors, through financial intermediaries unless the purchase is part of:
●a retirement plan which held the Fund prior to this closure,
●an automatic reinvestment of a distribution made by the Fund, or
●a de minimis annual rebalancing approved by a member of the Grandeur Peak client team.
Also, effective as of the close of business on February 26, 2021, the Grandeur Peak Emerging Markets Opportunities Fund will close to new investors seeking to purchase shares of the Fund through third party intermediaries subject to certain exceptions for financial advisors with an established position in the Fund and participants in certain qualified retirement plans with an existing position in the Fund.
The Funds remain open to purchases from existing investors, and to new investors who purchase directly from Grandeur Peak Funds.
The Funds retain the right to make exceptions to any Fund closure or limitation on purchases.
INVESTORS SHOULD RETAIN THIS SUPPLEMENT FOR FUTURE REFERENCE

#9
"Paying Too Much in Fees
Fees are the silent killer. As Dividend Growth Investor once tweeted:
If you invested $1,000 in Berkshire Hathaway in 1965, by 2009 your investment would have been worth $4.3 million.
If Buffett had set up Berkshire as a hedge fund, and charged a 2% annual fee plus 20% of any gains, the investor would have been left with only $300,000.
That’s a 10x difference because of fees!"
ARTICLE HERE